Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Bitdeer To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Bitdeer between June 6, 2024 and November 10, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Dec. 17, 2025 /PRNewswire/ -- Faruqi & Faruqi ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Bitdeer Technologies Group due to alleged violations of federal securities laws related to misleading statements about the company's SEALMINER A4 project and its delayed chip development [2][4]. Financial Performance - Bitdeer reported a third-quarter earnings per share of -$1.28, which significantly missed the consensus estimate of -$0.22, leading to a stock price drop of $2.63 (14.9%) to close at $15.02 on November 11, 2025 [5]. - Following a fire incident at its construction facility, Bitdeer's stock fell an additional $2.83 (20.3%) to close at $11.11 on November 13, 2025 [6]. Legal Proceedings - A federal securities class action has been filed against Bitdeer, with a deadline of February 2, 2026, for investors to seek the role of lead plaintiff [2][7]. - The lead plaintiff is defined as the investor with the largest financial interest who directs and oversees the litigation on behalf of the class [7]. Company Background - Faruqi & Faruqi, LLP is a national securities law firm that has recovered hundreds of millions of dollars for investors since its establishment in 1995 [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, Inc. due to allegations of misleading statements regarding the efficacy of its drug Efzofitimod, which led to significant financial losses for investors [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in aTyr between January 16, 2025, and September 12, 2025, to discuss their legal rights [1]. - There is a deadline of December 8, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against aTyr [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Allegations Against aTyr - The complaint alleges that aTyr and its executives violated federal securities laws by making false and misleading statements about Efzofitimod, particularly regarding its ability to allow patients to taper off steroid usage [4]. - In the EFZO-FIT study, efzofitimod showed no significant change in mean daily oral corticosteroid (OCS) dose at week 48, with a reduction of 2.79 mg for the drug compared to 3.52 mg for placebo [5]. - The study reported that complete steroid withdrawal was achieved in 52.6% of patients treated with efzofitimod versus 40.2% on placebo [5]. Group 3: Market Impact - Following the release of the study results, aTyr's stock price plummeted by 83.25%, dropping from a market close of $6.03 on September 12 to $1.01 on September 15 [5].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Bitdeer To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Bitdeer between June 6, 2024 and November 10, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Faruqi & ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Molina Healthcare, Inc. due to allegations of violations of federal securities laws related to misleading statements and undisclosed adverse facts affecting the company's financial performance [2][5]. Summary by Sections Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Molina to contact them regarding their legal options, particularly for those who purchased securities between February 5, 2025, and July 23, 2025 [1][2]. Allegations Against Molina - The complaint alleges that Molina and its executives made false or misleading statements and failed to disclose critical information, including: - Material adverse facts about the company's medical cost trend assumptions [5]. - A dislocation between premium rates and medical costs [5]. - Dependency on low utilization of behavioral health, pharmacy, and inpatient and outpatient services for near-term growth [5]. - Likelihood of substantial cuts to financial guidance for fiscal year 2025 [5]. - Misleading positive statements regarding the company's business and prospects [5]. Financial Performance and Stock Impact - On July 7, 2025, Molina announced second-quarter financial results, revealing adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures, leading to a 10.2% cut in full-year earnings guidance from at least $24.50 to a range of $21.50 to $22.50 per share [6]. - Following this announcement, Molina's stock price fell by $6.97, or 2.9%, closing at $232.61 per share on July 7, 2025 [6]. - On July 23, 2025, Molina further slashed its full-year earnings guidance, reporting GAAP net income of $4.75 per diluted share for the second quarter, an 8% decrease year-over-year, and cutting full-year adjusted earnings guidance to no less than $19.00 per diluted share, representing a 13.6% reduction [7][8]. - This led to a significant drop in Molina's stock price by $32.03, or 16.84%, closing at $158.22 per share on July 24, 2025 [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MoonLake (NASDAQ: MLTX) due to allegations of false and misleading statements regarding its product SLK, which failed to demonstrate competitive efficacy compared to BIMZELX, leading to a significant stock price drop [1][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in MoonLake between March 10, 2024, and September 29, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against MoonLake, with a deadline of December 15, 2025, for investors to seek the role of lead plaintiff [1][5]. Group 2: Allegations Against MoonLake - The complaint alleges that MoonLake and its executives violated federal securities laws by making false statements and failing to disclose material facts about the differences between Nanobodies and monoclonal antibodies [3]. - Specific allegations include that SLK and BIMZELX share the same molecular targets, and that SLK's unique structure does not provide superior clinical benefits or efficacy [3]. Group 3: Stock Performance Impact - Following the announcement of the Phase 3 VELA program results on September 28, 2025, which showed SLK's lack of competitive efficacy, MoonLake's stock price fell by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Jasper Therapeutics, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and lack of proper controls in manufacturing processes [3][5]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the November 18, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against Jasper [3]. - Investors who suffered losses in Jasper between November 30, 2023, and July 3, 2025, are encouraged to contact the firm to discuss their legal rights [1][3]. Group 2: Allegations Against Jasper - The complaint alleges that Jasper lacked necessary controls to ensure third-party manufacturers complied with cGMP regulations, which could negatively impact clinical trial results and the commercial prospects of its products, including briquilimab [5]. - The failure to disclose these issues has led to overstated business and financial prospects for Jasper, making public statements materially false and misleading [5]. Group 3: Impact of Recent Developments - On July 7, 2025, Jasper reported issues with a drug product lot used in clinical trials, leading to a significant drop in stock price by $3.73 per share, or 55.1%, closing at $3.04 per share [6]. - The company announced a halt in the ETESIAN Study and paused development in asthma and SCID, alongside plans for cost-cutting measures and potential restructuring to extend its financial runway [6].

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Semler Scientific did not disclose a material investigation by the United States Department of Justice (the "DOJ") into violations of the False Claims Act, while discussing possible violations of the False Claims (and aggressive DOJ enforcement thereof) in hypothetical terms; and (2) as a result, defendants public stat ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MoonLake (NASDAQ: MLTX) due to allegations of violations of federal securities laws, particularly concerning misleading statements about its product SLK compared to BIMZELX [4][6]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against MoonLake [4]. - Investors who suffered losses in MoonLake between March 10, 2024, and September 29, 2025, are encouraged to contact the firm to discuss their legal rights [1][9]. - The complaint alleges that MoonLake and its executives made false statements regarding the efficacy and clinical benefits of SLK compared to traditional monoclonal antibodies [6]. Group 2: Stock Performance and Market Reaction - Following the announcement of disappointing results from the Phase 3 VELA program on September 28, 2025, MoonLake's stock price fell by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [7]. - The results indicated that SLK did not demonstrate competitive efficacy relative to BIMZELX, leading to significant investor losses [7]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [5]. - The firm has offices in New York, Pennsylvania, California, and Georgia, indicating a broad operational footprint [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against RxSight, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and undisclosed challenges affecting the company's performance [4][6]. Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses exceeding $75,000 in RxSight between May 7, 2024, and July 8, 2025, to discuss their legal options [1]. - There is a deadline of September 22, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against RxSight [4]. - The complaint alleges that RxSight and its executives made false statements regarding the company's sales and utilization, overstated product demand, and failed to meet previously issued financial guidance for fiscal year 2025 [6]. Group 2: Financial Performance and Market Reaction - On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, indicating significant declines in LDD sales, LAL utilization, and overall revenue, leading to a lowered full-year guidance by approximately $42.5 million at the midpoint [7]. - Following the announcement, RxSight's stock price fell by $4.84, or 37.8%, closing at $7.95 per share on July 9, 2025, with unusually heavy trading volume [7].